INVESTOR RELATIONS

---

Due to demand in requests, we are excited to announce that you may now purchase ownership shares in ECNALAB, LLC, a California Limited Liability Company, and The Fentanyl Test.

ECNALAB, LLC is the owner-distributor of A47 - The Fentanyl Test. (“TFT”). The Fentanyl Test is the first and only FDA Cleared, and CLIA-waived over the counter dip-card urine test for at-home use. With a cut-off level of 1ng/mL and with accuracy over 99.4%, TFT will be soon be on all drug stores’ and retail stores’ shelves. TFT should be in every home with a suspected addict, or with children, for families to test randomly and at will without incurring the costs or wait times for results from a lab. 

We are targeting all prisons and jails, probation offices, local, state and federal government for our bulk, CLIA-waived and FDA Cleared testing strips with the intention to provide evidence of violations and crimes to court systems. This test will save countless lives.

In addition, TFT is the only Harm Reduction test that can test all surfaces for fentanyl, all powders, gels, pastes and even liquids, that preserves the tested substance for use or for evidence in a crime. 100% of the tested substance will be preserved. With a cut-off level of 1ng/mL (a grain of salt), and over 99.4% accuracy, TFT should be in every DHS and border security enforcement officer’s hands, every law enforcement officer's hands, every school, hospital, rehab, and anywhere fentanyl can be found that can cause accidental poisoning. While TFT nor ECNALAB, LLC advocates drug use, our Harm Reduction tests can test users’ substances and keep them safe from accidental poisoning and therefore, from death.

TFT will revolutionize testing, help in curbing the fentanyl epidemic, clean up our prisons, give
corrections, parole and probation officers a way to test their wards for fentanyl without shipping the samples off to labs incurring costs and lengthy wait times for results, and above all, save countless lives.

ECNALAB, LLC and The Fentanyl Test are listing 5,000 shares of Common Stock ownership
shares based on a $25,000,000.00 valuation that encompasses over $35,000,000.00 of inventory, all FDA Clearance expenses, CLIA-waiver expenses, manufacturing and shipping logistics expenses, national and international legal and healthcare compliance expenses, as well as our cutting edge technologies that are more accurate than labs and test for the lowest amount of any test, anywhere today. The 5,000 shares will be listed at a value of $500.00 per share, and account for 10% platform equity.

No investment is without risk. It is recommended that you speak with a financial or investment advisor prior to making your investment decisions.